Serotype prevalence and antibiotic resistance in Streptococcus pneumoniae clinical isolates among global populations

Hackel, Meredith; Lascols, Christine; Bouchillon, S.; Hilton, Betsy; Morgenstern, Diana; Purdy, Jay

doi:10.1016/j.vaccine.2013.07.054

Cited by 109 publications

(94 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is evidence that the increase in disease caused by serotype 19A is also universally related to the increase in antibiotic use and therefore the trend of antibiotic resistance observed in this particular serotype. 25 , 30 Moreover, there is a rise in infection from antibiotic-resistant strains seen in countries without a national pediatric vaccination program, leaving room for uncertainty whether the spike in 19A, and antibiotic-resistance in this strain, is solely from the introduction of PCV7. 30 As noted in a 2013 study, rates of antibiotic-resistance tend to vary from region to region and are influenced by such factors as serotype epidemiology of that region, vaccination programs, and antibiotic usage.…”

Section: Discussionmentioning

confidence: 99%

“…30 As noted in a 2013 study, rates of antibiotic-resistance tend to vary from region to region and are influenced by such factors as serotype epidemiology of that region, vaccination programs, and antibiotic usage. 25 Additionally, the use of conjugate vaccines against S. pneumoniae has led to a reduction in antibiotic use to treat these infections, which hopefully lessens the pressure for resistance to evolve. 46 This further corroborates the belief that both antibiotic-resistance and serotype replacement/switching are not solely influenced by vaccination programs, but act via natural and outside factors.…”

Section: Discussionmentioning

confidence: 99%

“…The most common serotypes seen in children are 6A, 14,19A, and 19F, 25 while the most prevalent in adults are 3, 6A, 7F, and 19A. 5 Among pneumococcal diseases, serotypes 1, 2, 4, 6A, 6B, 7F, 8, 9V, 14, 18C, 19F, and 23F are dominantly associated with IPD worldwide.…”

Section: Characteristics Of the Bacteriummentioning

confidence: 99%

“…30 Serotypes 6A, 6B, 9V, 14, 15A, 19F, and 23F have also shown the most antibiotic-resistance to penicillin and erythromycin, with many of these serotypes being included in the vaccines. 25 A positive side to this is that many of these vaccine type serotypes, while showing antibiotic resistance, have decreased in frequency since the introduction of the conjugate vaccine. Importantly, the introduction of PCV13 has led to a 45% decrease in IPD caused by 19A in young children.…”

Section: Characteristics Of the Bacteriummentioning

confidence: 99%

“…24 Slight increases in strain 19F, 6A, 16F, 23A, and 35 were also observed in adults. 24 , 25 , 30 The increase in strains 19A and 3 is particularly alarming since these two serotypes are commonly associated with IPD. The post PCV7 era also witnessed an increase in non-vaccine type IPD in the elderly, with this increase being more pronounced than the increase that was observed in children under five.…”

Section: Characteristics Of the Bacteriummentioning

confidence: 99%

See 4 more Smart Citations

Current status and future directions of invasive pneumococcal diseases and prophylactic approaches to control them

Wantuch

Avci

2018

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Streptococcus pneumoniae is a major human bacterial pathogen responsible for millions of deaths each year and significantly more illnesses worldwide. With over 90 different serotypes, providing effective vaccine programs has been a continuing challenge. Since 1983, the world has been introduced to four different pneumococcal vaccines (PPSV23, PCV7, PCV10, and PCV13) each with their own complications and successes. Since vaccination programs began, a decrease in the overall rate of pneumococcal pneumonia and associated diseases has been observed, notably in higher risk populations. However, with a decrease in incidence of vaccine type pneumococcal serotypes, increases in non-vaccine serotypes of the bacteria have been observed along with serotype switching. Additionally, a rise in antibiotic resistant strains of S. pneumoniae is noted. Here we discuss both the positive and negative clinical manifestations of pneumonia vaccine programs and discuss the challenges in pneumococcal vaccine design.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Characteristics Of the Bacteriummentioning

confidence: 99%

Section: Characteristics Of the Bacteriummentioning

confidence: 99%

Section: Characteristics Of the Bacteriummentioning

confidence: 99%

See 3 more Smart Citations

Current status and future directions of invasive pneumococcal diseases and prophylactic approaches to control them

Wantuch

Avci

2018

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

Streptococcus pneumoniae and chronic endobronchial infections in childhood

Hare

Leach

Smith‐Vaughan

et al. 2017

Pediatric Pulmonology

View full text Add to dashboard Cite

Streptococcus pneumoniae (pneumococcus) is the main cause of bacterial pneumonia worldwide and has been studied extensively in this context. However, its role in chronic endobronchial infections and accompanying lower airway neutrophilic infiltration has received little attention. Severe and recurrent pneumonia are risk factors for chronic suppurative lung disease (CSLD) and bronchiectasis; the latter causes considerable morbidity and, in some populations, premature death in children and adults. Protracted bacterial bronchitis (PBB) is another chronic endobronchial infection associated with substantial morbidity. In some children, PBB may progress to bronchiectasis. Although nontypeable Haemophilus influenzae is the main pathogen in PBB, CSLD and bronchiectasis, pneumococci are isolated commonly from the lower airways of children with these diagnoses. Here we review what is known currently about pneumococci in PBB, CSLD and bronchiectasis, including the importance of pneumococcal nasopharyngeal colonization and how persistence in the lower airways may contribute to the pathogenesis of these chronic pulmonary disorders. Antibiotic treatments, particularly long-term azithromycin therapy, are discussed together with antibiotic resistance and the impact of pneumococcal conjugate vaccines. Important areas requiring further investigation are identified, including immune responses associated with pneumococcal lower airway infection, alone and in combination with other respiratory pathogens, and microarray serotyping to improve detection of carriage and infection by multiple serotypes. Genome wide association studies of pneumococci from the upper and lower airways will help identify virulence and resistance determinants, including potential therapeutic targets and vaccine antigens to treat and prevent endobronchial infections. Much work is needed, but the benefits will be substantial.

show abstract

The Role of Vaccines in Combating Antimicrobial Resistance

Hegde¹

2023

Handbook on Antimicrobial Resistance

View full text Add to dashboard Cite

Serotype prevalence and antibiotic resistance in Streptococcus pneumoniae clinical isolates among global populations

Cited by 109 publications

References 33 publications

Current status and future directions of invasive pneumococcal diseases and prophylactic approaches to control them

Current status and future directions of invasive pneumococcal diseases and prophylactic approaches to control them

Streptococcus pneumoniae and chronic endobronchial infections in childhood

The Role of Vaccines in Combating Antimicrobial Resistance

Contact Info

Product

Resources

About